Drug Trial Radar · NCT00955968
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,653
Actual
Start
Jan 1, 2010
Primary completion
Aug 31, 2016
Study completion Aug 31, 2016
Sponsor
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Aug 10, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a randomized strategy trial conducted among women who received highly active antiretroviral therapy (HAART) during pregnancy for purposes of prevention of mother-to-child transmission (PMTCT) of HIV but did not otherwise meet criteria to initiate HAART for their own health. The study was designed to determine whether continuation of HAART after delivery or other pregnancy outcome reduced morbidity and mortality compared to discontinuation and re-initiation of HAART when protocol specified criteria were met.
Conditions
- HIV Infection
Interventions
Highly active antiretroviral therapy (HAART)Drug
A combination of three or more HIV medications belonging to two or more drug classes. The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or DeathTime frame: From study entry to study termination, all participants were followed until July 7, 2015 (an average of 125 weeks of follow-up).
Locations
50 sites in 9 countries. Site status is shown where the registry gives one.
University of Southern California MCA Center (5048)
Alhambra, California
David Geffen School of Medicine at UCLA (5112)
Los Angeles, California
UCSD Mother-Child-Adolescent HIV Program (4601)
San Diego, California
Harbor (UCLA) Medical Center (5045)
Torrance, California
University of Colorado (5052)
Aurora, Colorado
Howard University (5044)
Washington D.C., District of Columbia
Georgetown University (1008)
Washington D.C., District of Columbia
Washington Hospital Center (5023)
Washington D.C., District of Columbia
Children's Diagnostic and Treatment Center (5055)
Fort Lauderdale, Florida
University of Florida at Jacksonville (5051)
Jacksonville, Florida
University of Miami Pediatric/Perinatal Clinical Research Site (4201)
Miami, Florida
University of South Florida at Tampa (5018)
Tampa, Florida
Ann & Robert H Lurie Children's Hospital of Chicago (4001)
Chicago, Illinois
Tulane University (5095)
New Orleans, Louisiana
Johns Hopkins University School of Medicine (5092)
Baltimore, Maryland
Boston Medical Center (5011)
Boston, Massachusetts
Wayne State University/Children's Hospital of Michigan (5041)
Detroit, Michigan
Metropolitan Hospital (5003)
New York, New York
SUNY Stony Brook University Medical Center (5040)
Stony Brook, New York
Bronx-Lebanon Hospital Center (5114)
The Bronx, New York
Jacobi Medical Center (5013)
The Bronx, New York
Duke University Medical Center (4701)
Durham, North Carolina
Pitt CRS (1001)
Pittsburgh, Pennsylvania
St Jude Children's Research Hospital (6501)
Memphis, Tennessee
Baylor College of Medicine Texas Children's Hospital (3801)
Houston, Texas
Seattle Children's Hospital (5017)
Seattle, Washington
Hospital General de Agudos (5082)
Buenos Aires, Argentina
Gaborone Prevention/Treatment Clinical Research Site (12701)
Gaborone, Botswana
Molepolole Prevention/Treatment Clinical Research Site (12702)
Gaborone, Botswana
School of Medicine, University of Minas Gerais - FUNDEP (5073)
Belo Horizonte, Brazil
University Caxias do Sul (5084)
Caxias do Sul, Brazil
Hospital Nossa Senhora da Conceicao (5117)
Porto Alegre, Brazil
Hospital Santa Casa (5098)
Porto Alegre, Brazil
Hospital dos Servidores do Estado (5072)
Rio de Janeiro, Brazil
Hospital Geral De Nova Igaucu (5097)
Rio de Janeiro, Brazil
Instituto de Puericultura E Pediatria Martagao Geseira - FUJB (5071)
Rio de Janeiro, Brazil
Ribeirao Preto Medical School, University of Sao Paulo (5074)
São Paulo, Brazil
Guangxi Center for HIV/AIDS Prevention and Control (30274)
Nanning, Guangxi, China
Les Centres GHESKIO (30022)
Port-au-Prince, Haiti
IMPACTA Barranco Clinical Research Site (11301)
Lima, Peru
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.